TY - JOUR
T1 - Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy
T2 - The European Metachromatic Leukodystrophy initiative (MLDi)
AU - Schoenmakers, Daphne H.
AU - Beerepoot, Shanice
AU - van den Berg, Sibren
AU - Adang, Laura
AU - Bley, Annette
AU - Boelens, Jaap Jan
AU - Fumagalli, Francesca
AU - Goettsch, Wim G.
AU - Grønborg, Sabine
AU - Groeschel, Samuel
AU - van Hasselt, Peter M.
AU - Hollak, Carla E.M.
AU - Lindemans, Caroline
AU - Mochel, Fanny
AU - Mol, Peter G.M.
AU - Sevin, Caroline
AU - Zerem, Ayelet
AU - Schöls, Ludger
AU - Wolf, Nicole I.
N1 - © 2022. The Author(s).
PY - 2022/2/14
Y1 - 2022/2/14
N2 - Background: Metachromatic Leukodystrophy (MLD) is a rare lysosomal disorder. Patients suffer from relentless neurological deterioration leading to premature death. Recently, new treatment modalities, including gene therapy and enzyme replacement therapy, have been developed. Those advances increase the need for high-quality research infrastructure to adequately compare treatments, execute post-marketing surveillance, and perform health technology assessments (HTA). To facilitate this, a group of MLD experts started the MLD initiative (MLDi) and initiated an academia-led European MLD registry: the MLDi. An expert-based consensus procedure, namely a modified Delphi procedure, was used to determine the data elements required to answer academic, regulatory, and HTA research questions. Results: Three distinct sets of data elements were defined by the 13-member expert panel. The minimal set (n = 13) contained demographics and basic disease characteristics. The core set (n = 55) included functional status scores in terms of motor, manual, speech and eating abilities, and causal and supportive treatment characteristics. Health-related quality of life scores were included that were also deemed necessary for HTA. The optional set (n = 31) contained additional clinical aspects, such as findings at neurological examination, detailed motor function, presence of peripheral neuropathy, gall bladder involvement and micturition. Conclusion: Using a modified Delphi procedure with physicians from the main expert centers, consensus was reached on a core set of data that can be collected retrospectively and prospectively. With this consensus-based approach, an important step towards harmonization was made. This unique dataset will support knowledge about the disease and facilitate regulatory requirements related to the launch of new treatments.
AB - Background: Metachromatic Leukodystrophy (MLD) is a rare lysosomal disorder. Patients suffer from relentless neurological deterioration leading to premature death. Recently, new treatment modalities, including gene therapy and enzyme replacement therapy, have been developed. Those advances increase the need for high-quality research infrastructure to adequately compare treatments, execute post-marketing surveillance, and perform health technology assessments (HTA). To facilitate this, a group of MLD experts started the MLD initiative (MLDi) and initiated an academia-led European MLD registry: the MLDi. An expert-based consensus procedure, namely a modified Delphi procedure, was used to determine the data elements required to answer academic, regulatory, and HTA research questions. Results: Three distinct sets of data elements were defined by the 13-member expert panel. The minimal set (n = 13) contained demographics and basic disease characteristics. The core set (n = 55) included functional status scores in terms of motor, manual, speech and eating abilities, and causal and supportive treatment characteristics. Health-related quality of life scores were included that were also deemed necessary for HTA. The optional set (n = 31) contained additional clinical aspects, such as findings at neurological examination, detailed motor function, presence of peripheral neuropathy, gall bladder involvement and micturition. Conclusion: Using a modified Delphi procedure with physicians from the main expert centers, consensus was reached on a core set of data that can be collected retrospectively and prospectively. With this consensus-based approach, an important step towards harmonization was made. This unique dataset will support knowledge about the disease and facilitate regulatory requirements related to the launch of new treatments.
KW - Delphi procedure
KW - Metachromatic leukodystrophy
KW - MLD
KW - Rare disease registry
KW - Rare diseases
KW - Humans
KW - Quality of Life
KW - Leukodystrophy, Metachromatic/genetics
KW - Registries
KW - Retrospective Studies
KW - Consensus
UR - http://www.scopus.com/inward/record.url?scp=85124618706&partnerID=8YFLogxK
U2 - 10.1186/s13023-022-02189-w
DO - 10.1186/s13023-022-02189-w
M3 - Article
C2 - 35164810
AN - SCOPUS:85124618706
SN - 1750-1172
VL - 17
SP - 48
JO - Orphanet Journal of Rare Diseases
JF - Orphanet Journal of Rare Diseases
IS - 1
M1 - 48
ER -